Sacubitril/Valsartan as a Cardiac Radioprotector
Sac/val attenuated structural and functional aspects of RHI and was well tolerated in animals when given with radiation. Clinical data suggest that ANP changes dynamically during radiation therapy and that sac/val is safe to take concurrently. Further investigation of sac/val as a cardiac radioprotector is warranted.
Authors
- David Grieve (ORCID: https://orcid.org/0000-0002-3655-7754)
- Mihaela Ghita (ORCID: https://orcid.org/0000-0002-2467-9156)
- B. Kerr (ORCID: https://orcid.org/0009-0006-1957-9843)
- Brian Herron
- Karl T. Butterworth (ORCID: https://orcid.org/0000-0001-7170-6789)
- Kathryn H. Brown (ORCID: https://orcid.org/0000-0003-0392-587X)
- Kevin Edgar (ORCID: https://orcid.org/0000-0002-8057-0104)
- Comer Siobhan
- Chris J Watson
- Arvin Suguna Seelan
- Narainrit Karuna
- Mark T Harbinson
- Corinne Faivre-Finn
- Alastair Greystoke
- Gerard M Walls
Institutions
- Queen's University Belfast (GB)
- Belfast Health and Social Care Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- The Northern Ireland Cancer Centre (GB)
- The Christie NHS Foundation Trust (GB)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.ijrobp.2026.02.203
- Primary Topic
- Effects of Radiation Exposure
- Type
- article
- Field-Weighted Citation Impact
- 0.00